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Background: Although the peptidyl-prolyl isomerase, cyclophilin-A (peptidyl-prolyl isomerase, PPIA), has been
studied for decades in the context of its intracellular functions, its extracellular roles as a major contributor to both
inflammation and multiple cancers have more recently emerged. A wide range of activities have been ascribed to
extracellular PPIA that include induction of cytokine and matrix metalloproteinase (MMP) secretion, which
potentially underlie its roles in inflammation and tumorigenesis. However, there have been conflicting reports
as to which particular signaling events are under extracellular PPIA regulation, which may be due to either
cell-dependent responses and/or the use of commercial preparations recently shown to be highly impure.
Methods: We have produced and validated the purity of recombinant PPIA in order to subject it to a comparative
analysis between different cell types. Specifically, we have used a combination of multiple methods such as
luciferase reporter screens, translocation assays, phosphorylation assays, and nuclear magnetic resonance to
compare extracellular PPIA activities in several different cell lines that included epithelial and monocytic cells.
Results: Our findings have revealed that extracellular PPIA activity is cell type-dependent and that PPIA signals via
multiple cellular receptors beyond the single transmembrane receptor previously identified, Extracellular Matrix
MetalloPRoteinase Inducer (EMMPRIN). Finally, while our studies provide important insight into the cell-specific
responses, they also indicate that there are consistent responses such as nuclear factor kappa B (NFκB) signaling
induced in all cell lines tested.
Conclusions: We conclude that although extracellular PPIA activates several common pathways, it also targets
different receptors in different cell types, resulting in a complex, integrated signaling network that is cell
type-specific.
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LeukemiaBackground
Cyclophilins (Cyps) are members of the immunophilin
family of enzymes that possess peptidyl-prolyl isomerase
(PPIase) activity whereby they catalyze the reversible cis/
trans interconversion of the imide bond in proline resi-
dues. Cyps are implicated in promoting different diseases
and involved in diverse pathological conditions including* Correspondence: Elan.Eisenmesser@ucdenver.edu
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reproduction in any medium, provided the orhuman immunodeficiency virus infection [1], hepatitis C
infection [2], arteriosclerosis [3], inflammation [4], and
multiple cancers [5]. The prototypical cyclophilin family
member, cyclophilin-A (PPIA), was initially discovered as
the intracellular target of cyclosporin-A over a quarter
century ago, yet only recently have the extracellular roles
of PPIA in inflammatory disorders and in driving dozens
of cancers emerged [6]. In fact, PPIA is now commonly
referred to as a cytokine [7,8]. Unlike several Cyps, PPIA
does not contain a signal peptide and is therefore secreted
by noncanonical mechanisms that include vesicular release
[9]. Many clinical reports have identified high levels ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ritis patients [10] and elevated levels in the peripheral
blood of cancer patients relative to healthy individuals [4].
Moreover, increased expression of PPIA leads to chemo-
therapy resistance in multiple cancers [11] and RNA inter-
ference (RNAi) of PPIA in a non-small cell lung cancer
model slowed tumor growth [12], thereby suggesting a
causative role in cancer progression. Such findings illus-
trate the potential of therapeutically targeting extracellular
PPIA but also the downstream events that PPIA may regu-
late, which is dependent on further characterization of
extracellular PPIA activities studied here.
The particular cellular targets of extracellular PPIA
and downstream signaling pathways have recently been
explored; however, these studies have often been met
with contradictory findings. For example, extracellular
PPIA has been shown to induce JNK and p38 phospho-
rylation in some studies but not in others [7,13,14].
Some of these detected differences may reflect differen-
tial responses from different cell types, i.e., endothelial
cells versus monocytes for JNK and p38. However, much
of this work has been further complicated by the findings
of Payeli et al. [15], which exposed the wide-spread use
of impure commercially purchased recombinant PPIA
preparations. Further confusion has centered on the role
of PPIA catalytic activity (i.e., cis/trans isomerization) on
its biological activity. For example, elegant biophysical
studies have shown that the isomerase activity of intra-
cellular PPIA regulates the cis/trans conformation state
of several biological targets, which in turn regulate their
downstream interactions [16]. Analogous to this, we have
shown that extracellular PPIA can catalyze isomerization
of the only known cellular protein receptor, Extracellular
Matrix MetalloProteinase Inducer (EMMPRIN), also
known as CD147 and Basigin, and that this occurs at the
membrane proximal region centered around EMMPRIN
Pro211 [17]. However, we also previously discovered that
the PPIA/EMMPRIN interaction is extremely weak
in vitro, on the order of millimolar affinity, potentially
alluding to the requirement of other unknown mediators
or other cellular targets of PPIA.
In this study we utilized highly purified recombinant
PPIA to probe its extracellular activities on multiple cell
lines that included both leukemic and pancreatic cancer
cells [18]. These particular cell lines were chosen since
they represent very different types of cancers, i.e., mono-
cytic leukemia cells and epithelial cells in pancreatic
cancer, therefore allowing us to probe the particular simi-
larities and differences that extracellular PPIA may regulate
in a range of cancers. Initial screens that employed over a
dozen luciferase reporters were followed with dose-
dependent luciferase reporter assays and other intracellular
signaling assays to probe ERK1/2 phosphorylation and
NFκB signaling that are all mediated by extracellularPPIA. Moreover, by utilizing mutations on both the PPIA
protein side as well as within the promoter regions of the
luciferase reporters, specificity was shown and downstream
promoter elements were identified. Collectively, our sys-
tematic study indicates that while some of the final acti-
vated transcription events mediated by extracellular PPIA
stimulation are shared (i.e., NFκB signaling), there are cell-
specific differences in activation networks (i.e., ERK1/2
phosphorylation), which may be reliant on multiple recep-
tors beyond the cellular EMMPRIN receptor.
Results
Recombinant purified PPIA is identical to that
previously described
Based on the work conducted by Payeli et al. [15], it is crit-
ical for any study that monitors the biological effects of re-
combinant PPIA to first show that this enzyme is of the
highest purity. Specifically, these authors took advantage
of the uniquely characteristic UV spectrum of PPIA and
have shown that much of the commercially available PPIA
used is highly impure. Thus, to investigate the biological
functions of extracellular PPIA, we purified recombinant
PPIA as we have recently described utilizing a rigorous
procedure that encompasses two ion-exchange columns
and a sizing column [17,18]. The endotoxin levels of
these recombinant preparations are identical to that
of the purified water used (<30 pg/ml) and the UV
spectrum is identical to the pure PPIA (Additional file
1: Figure S1) that has been previously described by
Payeli et al.
Extracellular PPIA stimulation leads to a wide range
of cellular responses
A comparative analysis of multiple cell lines was con-
ducted using luciferase reporter assays, since such assays
offer a highly sensitive quantitative analysis of the signal-
ing events under extracellular PPIA regulation. Initial
screens of 16 luciferase reporters were monitored with
recombinant PPIA and used with several cell lines
that included standard a model cell line - HEK293T cells
(Figure 1A), a monocytic leukemia cell line - MOLM13
(Figure 1B), a pancreatic cancer cell line - PANC-1 (Figure
1C), and a metastatic pancreatic cancer cell line - L3.6pL
(Figure 1D). The luciferase reporters used encode for the
promoters of multiple cytokines and matrix metalloprotei-
nases (MMPs), but also several binding elements that
directly report on the activity of the transcription factors
themselves such as hypoxia-responsive element (HRE) and
β-catenin binding element (βCate). These report on
hypoxia-inducible factor (HIF) and β-catenin activities,
respectively. The particular luciferase reporters were
chosen since their respective cytokines, MMPs, and tran-
scription factors have been implicated in both inflamma-
tion, tumorigenesis and metastasis and the chosen PPIA
Figure 1 Extracellular PPIA activity monitored through luciferase reporters assays. Sixteen luciferase reporters were used to monitor
the response to extracellular PPIA in several cell lines, which included the following: A) HEK293T cells, B) MOLM13 cells, C) PANC-1 cells,
and D) L3.6PL. Cells were transiently transfected with the indicated reporters and then stimulated with recombinant 25 μM PPIA as described in
Materials and Methods. Luciferase activity is shown as a fold-increase over the buffer control (Luc Fold-Increase). Dashed line (grey) indicate no
Luc Fold-Increase (i.e., unity). *Beta-Catenin (βCate) and *HRE refer to plasmids that comprise the transcription target sites for HIF and βCate
transcription factors, respectively. The remaining plasmids comprise the indicated promoters for each protein. Bars indicate the standard error
of two replicates.
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extracellular PPIA found in diseased tissue [6,10].
Both cell-specific and common responses were found
to be mediated by extracellular PPIA (Figure 1). For
example, since PPIA has previously been shown to in-
duce an increase in Interleukin (IL)-5 production in
PANC-1 cells [19], we sought to determine whether a
similar response could be induced in other cell types.
However, despite confirming that PPIA induced a rela-
tively high increase in IL-5 in PANC-1 cells (Figure 1C),
there was no similar response detected in any of the
other cell lines that included the other pancreatic cancer
cell line, L3.6pL (Figure 1A,B,D). The addition of extra-
cellular PPIA induced a luciferase reporter activity for
PPIA itself in all cell lines tested excluding MOLM13,
consistent with the role of increased intracellular PPIA
in malignant transformation [20]. PPIA induced MMP9
luciferase reporter activity in both MOLM13 and L3.6pL
cell lines. MMP9 production appears to be a general re-
sponse to extracellular PPIA in monocytic cell lines such
as MOLM13 as it has been observed in THP-1 cells as
well [21,22]. Previous studies utilizing commercially pur-
chased recombinant PPIA have suggested that PPIA sti-
mulates IL-6 in monocytic cells [23]. However, ourrecombinant PPIA did not induce the production of IL-6
in the monocytic MOLM13 cells, which is analogous to
the findings of Payeli et al. that have also shown that
monocytic cells do not produce IL-6 in response to
highly purified PPIA [15]. There are several reporters
that appear to be universally upregulated by extracellular
PPIA, which include NFκB, IL-8, and p21Cip1 (referred to
herein as p21). The general response of NFκB and IL-8
was further confirmed by multiple experiments below,
while the uniform increase in p21 levels observed for all
cell lines could suggest a noncanonical role of this cyclin
kinase inhibitor (CKI) in cancer progression. Consistent
with such a noncanonical role, PPIA did not induce cell-
cycle arrest in any of these cell lines within the same
24 h time period used for the luciferase based assays
(Additional file 2: Figure S2). In fact, an increase in p21
protein has previously been found to correlate to pan-
creatic cancer progression [24] and the complicated
array of post-transcriptional modifications to p21 have
been found to promote cell survival and not always
cell-cycle arrest [25].
Concerns regarding the commercial preparations of re-
combinant PPIA have recently emerged [15] and there-
fore, here we addressed both the purity and specificity of
Figure 2 Probing the involvement of the PPIA active site for
both its biological activity and catalytic activity. A) For PPIA
biologically activity, dose-dependent luciferase assays were
conducted as in Figure 1 for the most highly induced luciferase
reporter in each cell line using both wild type PPIA (white) and the
active site point mutation PPIA R55A (black). These include IL-6 in
HEK293T cells, IL-8 in MOLM13 cells, IL-5 in PANC-1 cells, and IL-8 in
L3.6pL cells. B) The 15N-HSQC spectrum of 1 mM 15N-labeled model
peptide substrate, GSFGPLRAGD, is shown alone with the associated
assignments for each amide (top). Note, two resonances are
observed corresponding to the slowly interconverting cis and trans
resonances. Catalysis of both the wild type PPIA (middle) and
mutant PPIA R55A (bottom) were assessed through ZZ-exchange
spectroscopy in the presence of 20 μM of each. ZZ-exchange
spectra are shown for the same 240 ms delay. Arrows denote the
appearance of exchange peaks due to PPIA-mediated enhancement
of the rate of cis/trans interconversion of the model peptide
substrate. We note that no exchange peaks were observed for
longer mixing times of PPIA R55A indicating no detectable catalytic
rate enhancement. All spectra were collected at 720 MHz at 10 C.
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cifically, IL-6 and IL-8 were recombinantly produced and
purified since, like PPIA, these cytokines are involved in
both inflammation and cancer progression [26,27]. The
specific response induced by recombinant PPIA was
shown by a comparative analysis with recombinant IL-6
where a differential response was observed in regard to
both MMP9 and p21 stimulation (Additional file 3:
Figure S3A). Like PPIA, IL-6 stimulated the activity of
luciferase reporters of IL-8 and NFκB, which is consist-
ent with previous observations of monocytes [28]. We
also showed that there is a cell-specific response between
IL-6 and IL-8 in regard to inducing PPIA luciferase
activity (Additional file 3: Figure S3B), showing that
these two interleukins that were purified similarly exhibit
differential activity rather than inducing a general effect.
Further confirmation of specificity was also indicated by a
significantly diminished response to a PPIA active site
mutant in all cell lines tested, the details of which are pre-
sented below. Thus, these comparative studies confirm
that the recombinant proteins utilized here induce specific
cellular responses.
PPIA activity is dose-dependent and partially reliant
on the PPIA active site
The most highly upregulated luciferase reporter induced by
PPIA within each cell line in Figure 1 was further probed in
a dose-dependent manner (Figure 2A, white). A dose–
response using recombinant PPIA was observed in each cell
line, which included IL-6 in HEK293T cells, IL-8 in
MOLM13 cells, IL-5 in PANC-1 cells, and IL-8 in L3.6pL
cells (Figure 2A). Such a dose–response over this range of
micromolar PPIA concentrations indicates that the overall
binding constant of extracellular PPIA is weak in nature.
This is consistent with previous reports that have described
micromolar affinities of PPIA to biological targets such as
the HIV-1 capsid protein [29] and peptides derived from
phage display libraries [30]. The weak affinity of PPIA inter-
actions has made the identification of PPIA binding part-
ners notoriously difficult via standard pull-down methods
[31]. However, the interaction is specific as indicated by the
diminished response to the active site mutant, PPIA R55A
(Figure 2A, black). This PPIA R55A point mutation has
been reported to comprise only 1 % of the enzymatic acti-
vity (i.e., PPIase activity) compared to the wild type enzyme
[32]. Therefore, an observed reduction in biological activity
for PPIA R55A relative to the wild type enzyme is often
used to indicate a role of enzymatic activity in biological
activity. However, caution must be taken in such a conclu-
sion since this same mutant engages substrates with an ap-
proximately 10-fold lower affinity than the wild type
enzyme as well [33], thereby making it difficult to decouple
the role of PPIA binding versus PPIA catalysis in biological
activity. Nonetheless, a comparative analysis of PPIA R55Ato that of the wild type PPIA indicates that the biological ac-
tivity in all cell lines is markedly reduced (Figure 2A), con-
firming an important role of the PPIA active site.
One potential concern is that the endogenous bacterial
cyclophilins may co-purify with the recombinant human
PPIA that is overexpressed, which was addressed here.
We wanted to address this since there remained some
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mutant (Figure 2A), suggesting that a non catalytic role
for extracellular PPIA may also be present. To probe
enzymatic activity and confirm no catalytic activity for
PPIA R55A, an 15N-labeled peptide was recombinantly
produced as we have previously described in order to
apply a highly sensitive NMR-based catalytic assay called
ZZ-exchange [17]. ZZ-exchange is ideal for quantifying
the rate of proline isomerization mediated by cyclophi-
lins as we have previously described [17,34] and the pep-
tide sequence, GSFGPDLRAGD, was based on a
previous phage display study for CypA [30]. For the
15N-labeled peptide alone, both the cis and trans confor-
mations are observed for several resonances (Figure 2B,
top), indicating two distinct chemical environments with
a slow uncatalyzed cis/trans interconversion of the
central proline as observed for other PPIA substrates
[17,35]. However, in the presence of catalytic concentra-
tions of PPIA the appearance of “exchange peaks” within
ZZ-exchange spectra of 15N-labeled substrate indicate
that PPIA enhances the inherently slow peptidyl-prolyl
isomerization (Figure 2B, middle). As expected, in the
presence of the active site mutant, PPIA R55A, there are
no detectable exchange peaks for the substrate and
therefore indicates that the catalytic efficiency is severely
impaired. Importantly, this atomic resolution description
also confirms the absence of a co-purified bacterial
cyclophilin that may be responsible for the residual bio-
logical activity observed for PPIA R55A. Therefore, there
may exist some interactions for extracellular PPIA that
either do not require the enzymatic activity of PPIA or
simply do not require the PPIA active site.
Extracellular PPIA activates IL-6 and IL-8 interleukins
via NFκB for multiple cell lines
Since many promoters that include proinflammatory
cytokines, such as IL-6 and IL-8, comprise NFκB binding
elements, we hypothesized that the NFκB pathway is
involved in this translational activation. This hypothesis
was initially prompted by our luciferase reporter screens
(Figure 1), yet was further tested here through several
experimental approaches.
For the first method, we examined the effect of extra-
cellular PPIA on NFκB translocation from the cytoplasm
to the nucleus. To examine translocation we employed
an elegant assay that monitors the fluorescence of a p65
chimera C-terminally tagged to the green fluorescent
protein (GFP) previously established by Schmid et al.
[36,37]. Specifically, all three adherent cell lines studied
here were transfected with a plasmid encoding for GFP-
p65, which included HEK293T cells (Figure 3A, top),
PANC-1 cells (Figure 3A, middle), and L3.6pL cells
(Figure 3A, bottom). Analogous to the findings of Schmid
et al. [37], which showed that TNFα induced GFP-p65translocation to the nucleus, treatment here with PPIA also
induced translocation in all three cell lines (Figure 3A, bot-
tom panels) whereas the control of buffer alone did not
(Figure 3A, top panels). Moreover, even the mutant PPIA
R55A was capable of inducing GFP-p65 translocation
(Additional file 4: Figure S4A), consistent with the residual
activity observed for this active site mutant with regard to
luciferase activity of reporter genes (Figure 2A). While these
results imply that extracellular PPIA induces IkB degra-
dation in order to allow for GFP-p65 translocation, we
confirmed this by direct visualization using immunocyto-
fluorescence (see Additional file 4: Figure S4B). Specifically,
addition of PPIA led to a decreased immunocytofluores-
cence signal for the specific IkBα isoform (Additional file 4:
Figure S4B, bottom panels) while buffer alone did not
(Additional file 4: Figure S4B, top panels). Thus, from these
data, we clearly show that extracellular PPIA is capable of
NFκB activation in all three adherent cell lines tested.
As a second approach, we confirmed that the NFκB
binding element is necessary for PPIA induction of lucifer-
ase reporters for both IL-6 and IL-8. Specifically, we uti-
lized mutations to the NFκB binding element within the
IL-6 promoter that had previously been shown to abrogate
IL-6 luciferase reporter activity induced by the potent
inflammatory peptide, bradykinin [38]. These NFκB pro-
moter mutations are referred to as Mut1 and Mut2 as
described in Materials and Methods. Since both HEK293T
and L3.6pL cells were positive for the IL-6 luciferase re-
porter (Figure 1A, D), these IL-6 promoter mutants were
tested in parallel to the wild type IL-6 luciferase reporter.
Analogous to bradykinin, PPIA stimulation of IL-6 was
also found to be reliant on the NFκB binding element as
shown by the abrogation of luciferase reporter activity in
both HEK293T and L3.6pL cells (Figure 3B). Additionally,
two similar mutations were made to the NFκB binding
element within the IL-8 promoter as described in
Materials and Methods and the analogous experiments
were conducted in MOLM13, PANC-1, and L3.6pL cells.
These cell lines were chosen since they all exhibited ap-
proximately a 3-fold increase in IL-8 luciferase reporter
activity upon stimulation with recombinant PPIA in Fig-
ure 1. Just as mutations to the NFκB binding element
within the IL-6 promoter abrogate a PPIA driven increase
in the IL-6 luciferase reporter activity, mutations to the
NFκB binding element within the IL-8 promoter lead to a
negligible response to PPIA (Figure 3C). Thus, the NFκB
binding element is required for extracellular PPIA stimu-
lation of multiple cytokines (i.e., IL-6 and IL-8).
ERK1/2 phosphorylation mediated by extracellular PPIA
is cell dependent
To further investigate pathways downstream of extracellu-
lar PPIA stimulation, we compared ERK1/2 phosphory-
lation in multiple cell lines (Figure 4). There has been
Figure 3 Characterizing extracellular PPIA-mediated activity of NFκB within multiple cell lines. A) An NFκB translocation assay was
conducted in several adherent cell lines, which included HEK293T cells (top), PANC-1 cells (middle), and L3.6pL cells (bottom) with the addition of
either buffer control or PPIA. Cells were transiently transfected with the p65-GFP plasmid (green, left panels) as well as DAPI stained (blue, middle
panels) and the merge is shown (green, right panels). B) PPIA-induced luciferase reporter activity was monitored for the wild type IL-6 reporter
(WT) and two mutations to the NFκB binding element (Mut1 and Mut2) for HEK293T and L3.6pL cells. C) PPIA-induced luciferase reporter activity
was monitored for the wild type IL-8 luciferase reporter (WT) and two mutations within the NFκB binding element (also called Mut1 and Mut2)
for MOLM13, PANC-1, and L3.6pL cells. PPIA-induced luciferase reporter activity was monitored as in Figure 1.
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phosphorylation in several cell lines that include mono-
cytes, macrophages, neuronal, and lung cancer epithelial
cells [13,14,22,23,39] and deregulation of ERK1/2 signaling
is implicated in many diseases including cancer [40]. Thus,
the same four cell lines used for screening luciferase repor-
ters in Figure 1 were also used to monitor PPIA-mediated
ERK1/2 phosphorylation (Figure 4A).
ERK1/2 activation was initially assessed with the
addition of 25 μM PPIA using western blot analysis and
then more quantitatively probed using a cytometric assay
(Figure 4). While no phosphorylation was observed in
either HEK293T or L3.6pL cells, phosphorylation
was observed for both MOLM13 and PANC-1 cells
(Figure 4A). Further analysis using a flow cytometric
assay described in Materials and Methods indicated a
characteristic timeframe for the increase in ERK1/2 phos-
phorylation for both MOLM13 and PANC-1 cells
(Figure 4B). No time-dependent change was observed for
HEK293T or L3.6pL cells in accord with the western
blot analysis (data not shown). It is important to note
that although the classical pathways that lead to ERK1/2
phosphorylation and NFκB transcription probed above
are independent, there are some studies that haveshown that these two pathways exhibit some cross-talk
[13,22,23,41]. However, the data presented here show
that PPIA stimulated NFκB activity in all cell lines tested
(Figure 3) while only a subset of these cell lines exhibit
an increase in ERK1/2 phosphorylation (Figure 4), which
also suggests that the two pathways may be independent.
The important point here is that extracellular PPIA
induces ERK1/2 phosphorylation in a cell-dependent
manner and, once again, there is also a differential
response within cell lines derived from the same type of
cancer (i.e., PANC-1 and L3.6pL cells).
Extracellular PPIA activity is reliant on cellular BSG as well
as other receptors
Much attention has focused on the interaction between
extracellular PPIA and its proposed cellular receptor,
BSG, prompting us to determine whether a PPIA/BSG
interaction may be critical for some of the observed
activities above [6]. Our overall results confirm that
cellular BSG is involved in some signal transduction
events but also implicate other as yet unknown receptors
that are targeted by extracellular PPIA.
Our initial studies focused on determining whether cellu-
lar BSG is important for the extracellular PPIA-mediated
Figure 4 Characterizing extracellular PPIA-mediated activation
of ERK1/2 phosphorylation within multiple cell lines. A) ERK1/2
phosphorylation in PPIA stimulated HEK293T, MOLM13, PANC-1, and
L3.6pL cells was determined by immunoblotting. Cells were treated
with either buffer alone (−) or 25 μM PPIA (+) for 10 min and stored
in SDS loading buffer for subsequent immunoblotting analysis of
pERK1/2 and total ERK1/2 as a control. B) PPIA-induced time-
dependent induction of ERK1/2 phosphorylation as monitored by
flow cytometry is shown for both MOLM13 and PANC-1 cells for the
indicated time points also stimulated with 25 μM PPIA. The data
shown represents the mean of fluorescence intensity (MFI) for each
time point measured in triplicate and normalized to the average
initial MFI.
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line observed in Figure 4. To this end, we utilized a specific
shRNA BSG knockdown (shBSG) as well as a control cell
line with a non coding shRNA knockdown (sh0) to com-
pare PPIA-induced ERK1/2 phosphorylation in a time-
dependent manner (Figure 5A, top). From densitometry,
the shBSG knockdown compared to sh0 in MOLM13 cells
was determined to be approximately 94 % (Figure 5A,
bottom). As expected, knockdown of BSG in MOLM13
cells resulted in a drastic decrease in PPIA-mediated
ERK1/2 phosphorylation. To account for the possibility
that PPIA may induce BSG cell surface expression within
the timeframe of the ERK1/2 phosphorylation assay, we
also monitored cellular BSG within the same 30 min
timeframe and found no detectable increase in BSG
expression in MOLM13 cells (Figure 5A, bottom), which
is consistent with the lack of PPIA-induced ERK1/2
phosphorylation. Cellular BSG has been shown to be cri-
tical for PPIA-mediated phosphorylation of ERK1/2 in
several other cell lines such as HeLa cells [42] and lung
cancer cells [14]. Thus, our data here clearly shows that
cellular BSG is also critical for PPIA-mediated ERK1/2
phosphorylation in MOLM13 cells.
We next determined whether cellular BSG is important
for an activity measured in our luciferase assays. We fo-
cused on PPIA-mediated upregulation of IL-8, since this
cytokine is a well-known contributor to inflammationand cancer progression [27]. Knockdown of cellular BSG
had a negligible effect on the activity of PPIA-mediated
upregulation of IL-8 reporter activity in MOLM13 cells
(Figure 5B, top). However, PPIA also induced cellular
expression of BSG within MOLM13 cells that was clearly
visible within the shBSG knockdown cells after the 24 h
period used to monitor the luciferase reporter (Figure 5B,
bottom). Thus, because there is simultaneous re-expression
of cellular BSG upon stimulation with recombinant PPIA,
BSG’s role in PPIA-mediated IL-8 upregulation cannot be
determined in MOLM13 cells. Therefore, we turned to
another monocytic cell line, U937 cells, and produced the
analogous stable knockdown cell lines produced in
MOLM13 cells. From densitometry, the shBSG knockdown
compared to sh0 in U937 cells was determined to be
approximately 83 % (Figure 5C, bottom). Interestingly,
cellular BSG was also dispensable for PPIA-mediated induc-
tion of IL-8 in U937 cells as IL-8 induction was unchanged
between shBSG and sh0 cells (Figure 5C, top) and no con-
comitant induction of cellular BSG within the same 24 h
period was observed (Figure 5C, bottom). Thus, our studies
here have shown that in at least some cell lines, extracellu-
lar PPIA stimulates IL-8 through another receptor other
than BSG and that PPIA stimulation of cellular BSG expres-
sion is cell-dependent.
PPIA binds heparin through its active site
Since PPIA stimulation of IL-8 appears to be indepen-
dent of cellular BSG in at least one monocytic cell line
(Figure 5C), we sought a direct confirmation of extracellular
PPIA binding to heparin, which is the other proposed cellu-
lar target of extracellular PPIA [1]. In fact, other cyclophilins
such as cyclophilin-B (CypB) also engage heparin [43], yet
this has not directly been shown for PPIA at atomic reso-
lution and a confirmation would potentially set the stage for
the search for other glycoprotein receptors beyond BSG.
Since we have previously shown that PPIA both binds and
catalyzes a single site within BSG that is adjacent to the
outer cellular membrane by NMR [17], here we also
employed NMR to probe the potential PPIA/heparin inter-
action. NMR is an ideal technique for probing low affinity
interactions such as those between PPIA and its targets. For
example, the PPIA/BSG interaction is an extremely low
affinity interaction that we have characterized by NMR [17]
and others have characterized low affinity intracellular PPIA
interactions using NMR as well [16].
The titration of heparin into a solution of recombinant
15N-labeled PPIA induced specific chemical shift changes
as monitored through 15N-HSQC spectra (Figure 6A).
Only active site residues exhibited chemical shift changes
(Figure 6B), indicating that heparin interactions are spe-
cific to this region. Amides that exhibit chemical shift
changes above the digital resolution of the indirect dimen-
sion (~0.1 ppm) include H54, R55, I56, G59, S77, G80,
Figure 5 Assessing the importance of cellular BSG for extracellular PPIA activity on monocytes. A) Top: ERK1/2 phosphorylation was
monitored in MOLM13 cells using a flow cytometric assay (as in Figure 4) for both sh0 cells (solid line) and shBSG cells (dashed line). Bottom:
Western blot analysis using the BSG antibody shows that shBSG cells exhibit a significant knockdown when compared to sh0 cells. No significant
increase in cellular BSG expression was observed in sh0 cells within this 30 min timeframe as assessed by western blot analysis. B) Top: In
MOLM13 cells, IL-8 luciferase reporter activity was monitored after stimulation with recombinant PPIA. Bottom: Cellular BSG was monitored via
western blot analysis both before and after 24 h stimulation with recombinant PPIA. C) In U937 cells, a similar analysis was conducted as in (B).
For all stimulations, 25 μM recombinant PPIA was used and β-actin was used as a loading control. Arrows denote both highly and lowly
glycosylated BSG as well as the β-actin loading control.
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K155. An estimate for the dissociation constant (KD) of
PPIA/heparin was calculated as 2.5 ± 0.3 mM utilizing
these chemical shift changes with a simultaneous fit to a
simple binding isotherm (Figure 6C). Such weak affinity is
on the order of that also determined in vitro for the PPIA/
BSG interaction [17]. However, it should be noted that the
commercially available heparin is a mixture of different
lengths and thus, the specific affinity to one particular
heparin may be much higher. Regardless, our findings in-
dicate that PPIA does indeed target heparin specifically
through its active site as previously postulated [44].Figure 6 Quantifying the PPIA interaction with heparin at atomic reso
complex with 3 mM heparin (red). B) Residues that exhibit chemical shifts g
dimensions are highlighted (red) and are all located within the PPIA active
titration with heparin, the binding isotherms were used to estimate a KD of
shift changes of K82 and T152. All experiments were conducted at 600 MHDiscussion
Using both epithelial cells and monocytic cells, we have
identified both similar and markedly different responses
to exogenous PPIA. Several of the key new findings
include the following: i) The biological activity of PPIA
was partially abrogated by a PPIA active site mutant
(Figure 2), thereby both confirming specificity and sug-
gesting that the PPIA active site is important for some of
its many biological activities. However, the important
and potentially novel finding here is that the PPIA active
site mutant still retains a significant residual biological
activity, despite the fact that this mutant is reported tolution. A) 15N-HSQC spectra of 0.5 mM 15N-PPIA alone (black) and in
reater than 0.1 ppm upon engaging heparin in either 15N or 1H
site. C) Based on the measured 15N-PPIA chemical shift changes upon
2.5 ± 0.3 mM. Shown are the binding isotherms for the 15N chemical
z at 25°C.
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This suggests that the PPIase activity of PPIA may not be
important for all of its extracellular functions, which is
analogous to recent findings that have suggested the PPIase
activity is not required for all of its intracellular functions
[45,46]. ii) Similarities were identified in response to PPIA,
which included the production of IL-8 and p21 (Figure 1)
as well as activation of NFκB (Figure 3). In fact, a novel
finding here is that the PPIA-mediated response for several
cytokines is completely reliant on the downstream activity
of NFκB and consistent with this, all cell lines also showed
translocation of NFκB from the cytoplasm to the nucleus
upon PPIA stimulation (Figure 3). These similarities may
suggest that extracellular PPIA contributes to the relatively
high concentrations of key factors such as IL-8 that drive
cancer progression [27] and p21 levels that have also been
found to correlate to the progression of pancreatic cancer
[24]. iii) Several differential responses were identified in re-
sponse to PPIA. These cell-dependent responses were
observed in regard to PPIA stimulation of ERK1/2 phos-
phorylation, indicating that the signaling pathways that lead
to NFκB translation are cell-dependent. Another novel find-
ing here is that there is a differential response observed for
cell lines even derived from the same cancer. Specifically,
the two pancreatic cell lines, PANC-1 and L3.6pL, exhibit a
markedly different response to extracellular PPIA with re-
gard to IL-5 and IL-6 (Figure 1C,D) as well as ERK1/2
phosphorylation (Figure 4). Differential responses to ex-
ogenous PPIA also hold true for the monocytic cell lines
used here as well, MOLM13 and U937 cells. Specifically,
despite the common myeloid lineage of both cell lines,
extracellular PPIA only induced cell surface expression of
BSG within MOLM13 cells, but not in U937 cells (Fig-
ure 5B,C). Nonetheless, our identification of PPIA-induced
cellular BSG expression has important implications for
cancer progression in regard to the relationships between
PPIA, BSG, and MMPs. Namely, our data show that in
some cell types, PPIA stimulates cellular BSG expression,
which is in turn a known regulator of many MMPs that
drive tumorigenesis [47]. iv) Extracellular PPIA was
not necessarily reliant on cellular BSG for all of its
activities (Figure 5). For example, knockdown of the cel-
lular BSG in monocytic cells resulted in abrogation of
PPIA-mediated ERK1/2 phosphorylation. However, knock-
down of cellular BSG did not result in a detectable change
in PPIA-mediated stimulation of IL-8, suggesting that BSG
is not the sole cellular target of extracellular PPIA and,
therefore, opening avenues for the further identification of
PPIA cellular receptors.
The identification of cellular BSG as a target for
extracellular PPIA has greatly enhanced the field of
PPIA-mediated signaling [6], yet studies such as those
conducted here reveal that PPIA signaling is far more
complex than previously thought. Specifically, extracellularPPIA likely interacts with multiple cellular receptors. For
example, our previous atomic resolution investigations with
PPIA and BSG revealed that these two proteins bind with
millimolar affinity and therefore may require other media-
tors to enhance their biological interactions [17]. This is
supported by our studies here that have shown recombinant
PPIA is biologically active at much lower concentrations
that are within the micromolar range, which is more reflect-
ive of those concentrations that have been detected in vivo
[10]. More importantly, the very fact that BSG is necessary
for PPIA stimulation of ERK1/2 phosphorylation (in
MOLM13 cells in Figure 5A), but dispensable for IL-8
stimulation (in U937 cells in Figure 5C) could imply that
there is at least one more cellular receptor beyond BSG.
This is further supported by the differential cellular
response imparted by extracellular PPIA (Figure 1 and
Figure 4), which may not be surprising in retrospect. For ex-
ample, intracellular PPIA interacts with numerous targets
that include intracellular regions of receptors such as pro-
lactin [48] along with multiple kinases [16]. Thus,
extracellular PPIA has likely also evolved to interact with
multiple extracellular targets thereby regulating many cel-
lular responses that are simply dependent on expressed
receptors. In fact, extracellular PPIA has recently been
shown to mediate polymerization of the extracellular pro-
tein hensin [49], which in turn mediates assembly of the
extracellular matrix. Previous studies using PANC-1 cells
have shown that PPIA-induction of IL-17 is only partially
reduced upon blocking cellular BSG, also suggesting that
other cellular receptors are involved in IL-17 stimulation
[19]. All of these findings have critical implications to a
field where BSG has been thought to be the only cellular
receptor. Unfortunately the identification of PPIA targets
has been met with limited success (both extracellular and
intracellular), which is likely due to the transient nature of
PPIA interactions that makes simple pull-down experi-
ments difficult. Future studies aimed at identifying the
other cellular receptors of PPIA will likely require recently
developed approaches that are more directed at low affin-
ity interactions such as crosslinking methods [50,51].
Thus, hensin and BSG already provide an initial short list
of the multiple proteins that extracellular PPIA engages,
yet several studies including ours here also suggest that
glycosaminoglycans or other potential cellular protein
receptors serve as other cellular targets. Our confirmation
that PPIA engages one such glycosaminoglycan directly
through its active site, i.e., heparin (Figure 6), supports
several previous studies that have indicated that these
glycans serve as the initial interactions of extracellular
cyclophilins with the cell surface [1,43,44,52].
Conclusions
The major outcome from the studies conducted here is
that extracellular PPIA induces cell-specific responses
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specific responses have important implications for the
rationale design of therapeutic strategies aimed at block-
ing extracellular PPIA functions during disease progres-
sion. Namely, our studies suggest that the initial cellular
targets and associated signaling events differ significantly
between cells and reveal the importance of characteriz-
ing extracellular PPIA functions within multiple cell
lines. In general, the notion of one ligand targeting one
receptor is a rare phenomenon (i.e., PPIA solely targeting
the cellular BSG receptor). The very fact that extracellu-
lar PPIA has been compared to cytokines that each have
multiple receptors also suggests that PPIA targets mul-
tiple cellular receptors that may in turn be expressed in
a cell type-dependent manner.
Methods
Protein expression and purification
All proteins encoded in pET vectors were transformed
into BL21/DE3 cells for subsequent growth and purifi-
cation. Wild type PPIA and a PPIA R55A mutant
were purified through a three-column purification as pre-
viously described [17]. The DNA encoding IL-6 and IL-8
were purchased from Open Biosystems (Huntsville, AL),
cloned into a pET15b vector and the mature forms were
expressed, refolded, and purified as we have previously
described for several proteins [17,53]. Endotoxin levels were
monitored by ToxinSensor Chromogenic LAL Endotoxin
Assay (GenScript). The final purified proteins were concen-
trated to 1–2 mM using Millipore concentrator and stored
at −80°C until use. PPIA and its mutant were diluted in
50 mM phosphate buffer, pH 6.5 while both interleukins
were diluted to the same buffer but with an additional
150 mM NaCl. These buffers were selected since repeated
cycles of freeze/thawing produced no visible precipitate.
We note that any additional salt added to recombinant
PPIA did result in precipitation upon freeze/thawing. All
proteins were sterilized prior to use in cell-based assays.
Cell culture
HEK293T, MOLM13, and U937 cells were a kind give
from Dr. Christopher C. Porter (Department of Pediatrics,
University of Colorado Denver). L3.6pL cells were a
kind gift from Dr. Isaiah J. Fidler, Department of Cancer
Biology, The University of Texas MD Anderson Cancer
Center). PANC-1 cells were purchased from ATCC (ATCC
Number CRL-1469). HEK293T, PANC-1, and L3.6pL and
cells were cultured in Dulbecco’s modified Eagle medium
with 10 % fetal bovine serum (FBS) at 37°C with 5 % CO2.
MOLM13 and U937 cells were cultured in RPMI 1640
medium with 10 % fetal bovine serum at 37°C with 5 %
CO2. Fresh media was replaced every 2 to 3 days. Under
the concentrations of PPIA utilized in this study, no cell
death was observed.Luciferase reporter assays
Luciferase reporter plasmids are described in Additional
file 5. In addition to the previously constructed muta-
tions to the NFκB binding element in the pGL3-IL-6 re-
porter [38], similar mutations were made here within the
pGL3-IL-8 reporter. Site directed mutagenesis was used
to construct each mutation, which were then confirmed
by sequencing. Specifically, the wild type NFκB binding
site within the IL-8 promoter comprises the
following sequence that was used as a template for site-
directed mutagenesis: 5’-TCAGTTGCAAATCGTG
GAATTTCCTCTGACATAATG-3’. The following primers
and their reverse complements were used to create pGL3-




For transfections of luciferase reporters, cells (1 ×105)
were plated into 6-well plates and cultured for 1 day in
complete medium, then transfected with 6 μg per well of re-
porter plasmids and 25 ng per well of Renilla luciferase
plasmid, using Turbofact (Fermentas). 24 h post-
transfection, cells were serum starved for 4 h and then sti-
mulated with the indicated concentrations of recombinant
proteins or buffer (as control) in media without FBS for an-
other 24 h. Firefly and Renilla luciferase activity were mea-
sured with the dual-luciferase reporter assay system
(Promega) and the former was normalized to the latter to
account for transfection efficiencies. Finally, results are pre-
sented as the fold-increase of cells (Luc Fold-Increase),
which is the ratio of cells treated with recombinant protein
over cells treated with the same amount of buffer control.
NFkB translocation
HEK293T, PANC-1, and L3.6pL cells were cultured on
glass coverslips in 6 well plates. To detect NFκB trans-
location from the cytoplasm to the nucleus, these cells
were transfected with 6 μg of a plasmid encoding for p65
and GFP for 24 h as described previously [54], which
was a kind gift from Dr. M. Lienhard Schmitz, University
of Bern, Department for Chemistry and Biochemistry,
Bern, Switzerland. Cells were then stimulated with
25 μM PPIA for 24 h and buffer was used as a control.
Hoechst 33342 dye (Sigma, St. Louis, MO) was used for
nuclear staining (blue). Cells were washed with PBS,
fixed with cold methanol for 10 min at 4°C, and analyzed
using a fluorescence microscope (Zeiss).
Western blotting, immunocytofluorescence and flow
cytometric analysis
For protein detection by western blot analysis, whole-cell
lysates were harvested and lysed for 30 min in ice using
100 μL of RIPA buffer. The lysates were cleared via centri-
fugation at 13,000 rpm for 10 min in a microcentrifuge.
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blotting with antibodies to unphosphorylated total ERK1/2
(ERK1/2) and phosphorylated ERK1/2 (pERK1/2) both pur-
chased from the same source (Cell Signaling) or antibodies
to BSG (R&D Systems). Ten μL of total lysate was sub-
jected to electrophoresis on SDS-PAGE gels and trans-
ferred to a PVDF membrane. The membranes were blocked
and incubated with primary and secondary antibodies
according to the manufacturer’s protocols. Signals were
developed using western LightningR Plus-ECL Enhanced
Chemiluminescent Substrate (PerkinElmer, Waltham, MA)
and exposed to X-ray film.
To assess ERK1/2 phosphorylation using flow cytome-
try, cells were cultured in 6-well plates at approximately
1x105 per well and treated with either PPIA at 25 μM or
buffer for the indicated times. The ERK1/2 phosphor-
ylation assay was quantified by flow cytometry using
anti-pERK1/2 (BD Biosciences) performed as we have
previously described [55].
For IkBα degradation, PANC-1, L3.6pL and HEK293T
were treated with 25 μM recombinant PPIA for 2 h. Cells
were fixed with methanol for 10 min at 4°C and blocked
with 3 % normal donkey serum (Jackson ImmunoResearch;
West Grove, PA) in PBS for 1 h. The cells were incubated
with rabbit IkBα antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) for 1 h at room temperature. The second-
ary antibody, Alexa Fluor 594 anti-rabbit IgG (Invitrogen
Corp., Carlsbad, CA), was applied for 1 h. Cells were
mounted with Vectashield medium containing DAPI
(Vector Laboratories, Burlingame, CA).
BSG knockdown in monocytes
Commercially available BSG shRNA lentiviral vectors
(pLKO.1 plasmids purchased from OpenBiosystems,
Huntsville, AL) were transfected into HEK293FT cells at
70 %-80 % confluency with 500 ng of the necessary viral
packaging vectors using TurboFect (Fermentas). Viral
packaging vectors included REV, GAG/Pol, and VSVG.
One mL of the supernatants comprising the viruses pro-
duced from these HEK293FT cells were then transduced
using 5x104 MOLM13 or U937 cells in the presence of
polybrene (Sigma) and puromycin resistance encoded
within the lentiviral shRNA was used to select for successful
transductions. A substantial BSG knockdown for both
MOLM13 and U937 cell lines was found for an BSG
shRNA that targets the 3’-UTR of the non coding region of
BSG, herein called shBSG, and was utilized for all knock-
downs described. A non-encoding shRNA purchased from
Addgene (Cambridge, MA), herein called sh0, was used as a
control.
Cell cycle analysis
Cells were plated in 6 well plates for 24 h, followed by
starvation for 4 h and then stimulated with either 25 μMPPIA or buffer for 24 h. After stimulation, cells were
stained overnight at 4°C with a solution containing
25 μg/mL propidium iodide, 0.3 % saponin, 0.1 mM
EDTA, and 2 Kunitz U/mL RNAse. The cells were ana-
lyzed for a sub-G1 peak using a Coulter Epics XL flow
cytometer (Beckman-Coulter, Hialeah, Florida). Peak vs.
integral gating was used to exclude doublet events from
the analysis. Data was collected for 10,000 cells. Modfit
LT (Verity Software House, Topsham, Maine) was used
for cell cycle and apoptotic peak modeling.NMR sample preparation and experiments
ZZ-exchange spectroscopy was used for assessing the cata-
lytic activity of both wild type PPIA and the PPIA R55A
mutant. ZZ-exchange spectroscopy was performed on a
Varian 720 at 10°C using 20 μM enzyme and 1 mM of a
recombinantly produced 15N-labeled peptide substrate
with the following resultant sequence: GSFGPDLRAGD.
This peptide was produced and its resonances assigned as
previously described by Schlegel et al. [17]. A 15N-edited
heteronuclear single quantum coherence (15N-HSQC) was
also collected on the free peptide substrate alone. NMR
buffer conditions were 50 mM NaPO4, pH 6.5, 1 mM
dithiothreitol with 5 % D2O. The resonance shifts of the
model peptide substrate were assigned via standard triple
resonance experiments as we have previously described for
proteins [17,53,56].
For assessing PPIA binding to heparin, PPIA was 15N-la-
beled and 15N-HSQC spectra were collected on a Varian
600 with increasing amounts of heparin derived from por-
cine intestinal mucosa (Sigma, catalogue number 9041-08-
1). The concentration of 15N-labeled PPIA was 0.5 mM
and final concentrations of heparin added were 0, 100,
500, 1000, 3000 μM. NMR buffer conditions were 50 mM
HEPES, pH 7.5, 1 mM dithiothritol with 5 % D2O.Statistical analysis
One-way ANOVA by GraphPad Prism 5 was used to
evaluate statistical differences among experimental groups.
A Dunnett's test was applied and a value of p< 0.05 was
considered significant (*). Data are shown here as the
mean±SEM from three independent experiments.Additional files
Additional file 1: Figure S1. Assessing the purity of recombinant PPIA.
A) UV spectrum of recombinantly purified PPIA. The atypical UV spectrum
of PPIA has been shown to be an important confirmation of its purity
[15]. B) 15N-HSQC spectrum of purified PPIA collected at 900 MHz at 25°C
along with the three-dimensional structure (inset).
Additional file 2: Figure S2. The effect of extracellular PPIA on cellular
proliferation. Cell cycle was monitored 24 h post incubation using FACS
analysis with either buffer alone or recombinant PPIA in (A) HEK293T cells,
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http://www.cancerci.com/content/12/1/19(B) MOLM13 cells, (C) PANC-1 cells, and (D) L3.6pL cells. No apparent
effect was observed.
Additional file 3: Figure S3. Probing the cell-specific responses to in-
house purified recombinant proteins. A) MOLM13 cells were used for a
comparative analysis of luciferase reporter assays stimulated with various
recombinantly purified proteins, which include recombinant PPIA and
recombinant IL-6. B) Luciferase reporter activity of PPIA was monitored for
both IL-6 (left) and IL-8 (right). All luciferase reporter activities were
conducted as in Figure 1.
Additional file 4: Figure S4. Further characterization of PPIA-mediated
activation of NFκB. A) An NFκB translocation assay was conducted as in
Figure 3A, but using the PPIA active site point mutation, PPIA R55A. B)
IκBα degradation is shown after treatment with recombinant PPIA.
Additional file 5: Luciferase Reporter Plasmid Sources.
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